Aging seniors to reap long-term health benefits from Edmonton-based artificial intelligence project
Aging seniors to reap long-term health benefits from Edmonton-based artificial intelligence project
Search
Health Canada approves NexGard® and NexGard Spectra™ for the reduction of Lyme disease
Health Canada approves NexGard® and NexGard Spectra™ for the reduction of Lyme disease
Boehringer Ingelheim Canada’s national program is helping people living with diabetes and heart failure by addressing health system gaps
Boehringer Ingelheim Canada’s national program is helping people living with diabetes and heart failure by addressing health system gaps
Vancouver General Hospital pilots new plant-rich menu items for health of patients and planet
Vancouver General Hospital pilots new plant-rich menu items for health of patients and planet
Human Health
Human Health
Animal Health Partnering Interests
In order to create the next generation of medical breakthroughs in animal health we need partners. Click here to view our animal health partnering interests.
Animal Health Products
Animal Health Products
Our culture
Our culture reflects who we are and is reflected in Our FOCUS and strong belief in Diversity, Equity and Inclusion as well as Sustainable Development.
Health Canada issues Notice of Compliance (NOC) for Jardiance® (empagliflozin) for the treatment of heart failure with reduced ejection fraction
Health Canada issues Notice of Compliance (NOC) for Jardiance® (empagliflozin) for the treatment of heart failure with reduced ejection fraction
Does your PRRS vaccine have sufficient “horsepower?”
Does your PRRS vaccine have sufficient “horsepower?”
University Health Network and Boehringer Ingelheim Canada partner to impact patients lives and help a healthcare system under strain
University Health Network and Boehringer Ingelheim Canada partner to impact patients lives and help a healthcare system under strain
More Potential
Boehringer Ingelheim steps up its commitment to sustainable development, building on its historical success in addressing unmet health needs and increasing its ambitions to tackle global health and societal challenges.
Science Focus
Science and Innovation - Human Health Innovation - Science Focus
New health projects empower Indigenous communities to address chronic diseases
New health projects empower Indigenous communities to address chronic diseases
Philanthropic partnership sets sights on sustainable improvements to health care
Philanthropic partnership sets sights on sustainable improvements to health care
Accelerating innovation in health : Boehringer Ingelheim and the Vector Institute to collaborate on AI
Accelerating innovation in health : Boehringer Ingelheim and the Vector Institute to collaborate on AI
Innovative health projects impact thousands of Indigenous Peoples in Canada
Innovative health projects impact thousands of Indigenous Peoples in Canada
See our Locations
We offer career development opportunities in over 170 locations across the world. Explore some of our featured locations.
Udder health during the dry period
Udder health during the dry period
Explore our company
Make your next career step at Boehringer Ingelheim. Explore our various fields to find out more about employment opportunities in your area of interest.
Saskatchewan Health Research Foundation and Boehringer Ingelheim Canada Partner to Improve Chronic Diseases Care in Saskatchewan’s Indigenous Communities
Saskatchewan Health Research Foundation and Boehringer Ingelheim Canada Partner to Improve Chronic Diseases Care in Saskatchewan’s Indigenous Communities
Human Health Partnering
Human Health Partnering
Improving health outcomes for patients living with interstitial lung disease and addressing the gaps in care is the aim of a new collaboration
Improving health outcomes for patients living with interstitial lung disease and addressing the gaps in care is the aim of a new collaboration
Health Canada approves OFEV® (nintedanib), the first and only therapy in Canada to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated ILD
Health Canada approves OFEV® (nintedanib), the first and only therapy in Canada to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated ILD
Code of Conduct
Our Code of Conduct sets the ethical standards that guides all our business activities. It´s about all of us. Each individual plays a vital role in bringing the Code of Conduct to live.